Advertisement

Recombinant DNA Approaches to Feline Leukemia Virus Immunization

  • Paul Luciw
  • Debbie Parkes
  • Gary Van Nest
  • Dino Dina
  • Kathleen Hendrix
  • Murray B. Gardner
Part of the Basic Life Sciences book series

Abstract

Retrovirus vaccines are in the limelight now more than ever before due to the etiologic involvement of retroviruses, human T-lymphotropic virus (HTLV-III/LAV) in the acquired immunodeficiency syndrome (AIDS) of man (1,5) and HTLV-I in certain human lymphomas (14). Experience with retrovi ruses and other viral vaccines in animal models is thus of great importance in guiding the way toward the most effective procedures for immunizing humans. Conventional vaccine approaches with inactivated or live attenuated retroviruses have been successful in some circumstances (7). However, these vaccines pose a number of economic and safety problems, primarily because of the tissue culture requirement for growing viruses. In view of these considerations, the new recombinant DNA technology offers the advantage of producing synthetic vaccines of greater purity, stability, safety, and cost-effectiveness (13). Researchers in private industry are playing an important role in developing such products.

Keywords

Live Virus Envelope Gene Persistent Viremia Detectable Viremia Modify Live Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barré-Sinoussi, F., J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Ve’zinet-Brun, C. Rouzious, W. Rosenbaum, and L. Montagnier (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syn-drome (AIDS). Science 220:868–871.PubMedCrossRefGoogle Scholar
  2. 2.
    Coffin, J. (1982) Structure of the retroviral genome. In RNA Tumor Viruses, R. Weiss, N. Teich, H. Varmus, and J. Coffin, eds. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 261–268.Google Scholar
  3. 3.
    Elder, J.H., and J.I. Mullins (1983) Nucleotide sequence of the envelope gene of Gardner-Arnstein feline leukemia virus B reveals unique sequence homologies with a murine mink cell focus-forming virus. J. Virol. 46:871–880.PubMedGoogle Scholar
  4. 4.
    Emini, E.A., B.A. Jameston, A.J. Lewis, and E. Wimmer (1983) Priming and induction of anti-poliovirus neutralizing antibodies by synthetic peptides. Nature 304:699–702.PubMedCrossRefGoogle Scholar
  5. 5.
    Gallo, R.C., S.Z. Salahuddin, M. Popovic, G.M. Shearer, M. Kaplan, B.F. Haynes, T.J. Palker, R. Redfield, J. Oleske, B. Safai, G. White, P. Foster, and P.D. Markham (1984) Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500–502.PubMedCrossRefGoogle Scholar
  6. 6.
    Gardner, M.B., and P. Marx (1985) Simian acquired immunodeficiency syndrome. Adv. Viral Onc. 5:57–81.Google Scholar
  7. 7.
    Gardner, M.B., N. Pedersen, P. Marx, R. Henrickson, P. Luciw, and R. Gilden (1985) Vaccination against virally induced animal tumors. In Immunity To Cancer, A.E. Reif and M.S. Mitchell, eds. Academic Press, New York, pp. 605–617.Google Scholar
  8. 8.
    Hardy, Jr., W.D., P.W. Hess, E.G. MacEwen, A.J. McClelland, E.E. Zuckerman, M. Essex, S.M. Cotter, and O. Jarrett (1976) Biology of fe-line leukemia virus in the natural environment. Cane. Res. 36:582–588.Google Scholar
  9. 9.
    Jarrett, O. (1974) Feline leukemia virus subgroups. In Feline Leukemia Virus, W.D. Hardy and A.J. McClelland, eds. Elsevier/North Holland, Amsterdam, pp. 473–479.Google Scholar
  10. 10.
    Jarrett, W., L. Mackey, O. Jarrett, H. Laird, and C. Hood (1974) Antibody response and virus survival in cats vaccinated against leukemia. Nature New Biology 248:230–232.CrossRefGoogle Scholar
  11. 11.
    Lutz, H., N.C. Petersen, and G.H. Theilen (1983) Course of feline leukemia virus infection and its detection by enzyme-linked immunosorbent assay and monoclonal antibodies. Am. J. Vet. Med. 44(11):2054–2059.Google Scholar
  12. 12.
    Mathes, L.E., M.G. Lewis, and R.G. Olsen (1980) Immunoprevention of feline leukemia: Efficacy testing and antigenic analysis of soluble tumor-cell antigen vaccine. In Feline Leukemic Virus, W.D. Hardy and A.J. McClelland, eds. Elsevier/North Holland, Amsterdam, pp. 211–216.Google Scholar
  13. 13.
    Norrby, E. (1983) Viral vaccines: The use of currently available products and future developments. Archives of Virology 75:163–177.CrossRefGoogle Scholar
  14. 14.
    Poiesz, B.J., R.W. Ruscetti, A.F. Gazdar, P.A. Bunn, J.D. Minna, and R.C. Gallo (1980) Detection and isolation of type C virus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci., USA 77:7415–7419.PubMedCrossRefGoogle Scholar
  15. 15.
    Sarma, P.S., and T. Log (1971) Viral interference in feline leukemia-sarcoma complex. Virology 44:352–358.PubMedCrossRefGoogle Scholar
  16. 16.
    Valenzuela, P., A. Medina, W.J. Rutter, G. Ammerer, and B.D. Hall (1982) Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298:347–350.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Paul Luciw
    • 1
  • Debbie Parkes
    • 1
  • Gary Van Nest
    • 1
  • Dino Dina
    • 1
  • Kathleen Hendrix
    • 2
  • Murray B. Gardner
    • 2
  1. 1.Chiron LaboratoryEmeryvilleUSA
  2. 2.Department of Medical Pathology School of MedicineUniversity of CaliforniaDavisUSA

Personalised recommendations